Skip to main content
Premium Trial:

Request an Annual Quote

Illumina to Build 150K-Square-Foot Facility in San Diego

NEW YORK (GenomeWeb) – Illumina will build a new 150,000-square-foot facility in San Diego to house manufacturing and logistics, the company and the city said on Tuesday.

When completed, the new space will add about 300 new "high-wage" jobs to the current 1,500 workers already employed by the firm, a spokesman for Illumina said. The new facility will be located at the company's headquarters campus, he added.

The immediate occupants in the space are anticipated to be groups from Illumina's reagent and manufacturing operations, and the company is targeting basic LEED certification, Gold or Silver level.

"We are deploying highly efficient electro-mechanical systems in the fit out, using best-in-class design to enhance energy conservation," the spokesman said. Completion of the space is anticipated by early in the second quarter of 2016.

According to a statement from the office of San Diego Mayor Kevin Faulconer, Illumina would be eligible to receive a $1.5 million tax rebate. San Diego will retain about 30 percent of Illumina's sale tax revenues as well as the current level of sales and use tax generated by the company, or about $1.3 million annually in the most recent year. After the $1.5 million tax rebate cap is reached or the term of the 10-year agreement has expired, San Diego would receive 100 percent of Illumina's tax revenue.

The agreement is scheduled for a vote by the City Council for the week of July 21.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more